Mutabon Ansiolitico (Amitriptyline Hydrochloride, Perphenazine)

Mutabon Ansiolitico combines a tricyclic antidepressant and a phenothiazine antipsychotic to treat mood and psychotic disorders.

• Depressive disorders: alleviates depressive symptoms and improves mood.
• Psychotic depression: reduces both depressive and psychotic features.
• Schizophrenia: helps control positive psychotic symptoms such as hallucinations and delusions.

• Amitriptyline inhibits the reuptake of norepinephrine and serotonin, increasing their synaptic concentrations, while Perphenazine antagonizes dopamine D2 receptors, decreasing dopaminergic neurotransmission. The dual action modulates both mood and psychotic pathways, providing therapeutic benefit in combined depressive‑psychotic states.

Adverse reactions may occur with the combined formulation.

Common Side Effects

• Dry mouth: reduced salivary flow.
• Sedation: drowsiness or fatigue.
• Constipation: slowed gastrointestinal motility.
• Weight gain: increased appetite or fluid retention.
• Orthostatic hypotension: dizziness upon standing.
• Blurred vision: transient visual disturbances.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, especially in high‑dose tricyclic use.
• Neuroleptic malignant syndrome: fever, muscle rigidity, autonomic instability.
• Seizures: heightened risk in predisposed individuals.
• Agranulocytosis: severe drop in white blood cells.
• Torsades de pointes: life‑threatening ventricular tachycardia.
• Hepatotoxicity: liver enzyme elevation or injury.

Before initiating therapy, consider patient‑specific factors and monitor for safety.

• Cardiac assessment: obtain baseline ECG in patients with cardiac history.
• CNS depression: avoid alcohol or other sedatives that may enhance drowsiness.
• Glaucoma: use cautiously in patients with narrow‑angle glaucoma.
• Elderly patients: start at low dose and titrate slowly to reduce fall risk.
• Pregnancy and lactation: discuss potential risks with the prescriber; data are limited.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Drug‑drug interactions can modify efficacy or increase toxicity.

Major Interactions (Avoid)

• MAO inhibitors: risk of hypertensive crisis or serotonin syndrome.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise amitriptyline levels.
• QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation.
• Anticholinergic drugs: increased dry mouth, constipation, urinary retention.
• Alcohol: potentiates sedative and hypotensive effects.